

**CK LIFE SCIENCES INTERNATIONAL (HOLDINGS) INCORPORATED:
THE COMPANY CLAIMS TO HAVE MADE A BREAKTHROUGH
IN THE TREATMENT OF CANCER!**

It may be difficult to believe for some people, but publicly listed CK Life Sciences International (Holdings) Incorporated (Code: 8222, The Growth Enterprise Market [The GEM] of The Stock Exchange of Hongkong Ltd) is on the verge of making a major breakthrough in the field of cancer research.

At least, that would appear to be the clear innuendo on reading the Third Quarterly Report of Company, released on October 31, 2003.

The Chairman of this Company is Mr Victor Li Tzar Kuoi, the Number One Son of Mr Li Ka Shing, the richest man in the world, the man, who controls publicly listed Cheung Kong (Holdings) Ltd (Code: 1, Main Board, The Stock Exchange of Hongkong Ltd), Hutchison Whampoa Ltd (Code: 13, Main Board, The Stock Exchange of Hongkong Ltd), tom.com Ltd (Code: 8001, The GEM, The Stock Exchange of Hongkong Ltd, and PCCW Ltd (Code: 8, Main Board, The Stock Exchange of Hongkong Ltd).

Chairman Victor Li Tzar Kuoi has told his shareholders that he was pleased to record that his Company had reported an Unaudited Profit Attributable to Shareholders of about \$HK253,000 for the Quarter, ended September 30, 2003.

That result compared with a Loss Attributable to Shareholders for the like 2002 quarter of about \$HK11.08 million.

For the first 9 months of this Financial Year, CK Life Sciences has been able to achieve an aggregate Net Profit Attributable to Shareholders of about \$HK731,000.

This 9-month result was on the back of a Turnover of about \$HK19.62 million, the Third Quarterly Report states.

That represents a Net Profit Margin of about 3.73 percent.

Note 2 to the Accounts states that the Turnover *'represents the net amount received and receivable from sales of eco-agriculture products – fertilisers and nutraceutical products.'*

Scanning the Consolidated Income Statement of CK Life Sciences shows, conclusively, that the Company earned about \$HK146.05 million from *'income from bank deposits and investments in financial instruments.'* (Note 3 to the Accounts)

Subtracting the income from bank deposits, etc, suggests that the Company continues to suffer a financial hemorrhage, which is not too dissimilar to that of the 2002-Year when it recorded a Loss Attributable to Shareholders of about \$HK60.45 million, during the first 9 months of that Year.

As at September 30, 2003, CK Life Sciences had about \$HK2.15 billion in cash, and about \$HK49.23 million in investments in securities.

That mountain of money was the residue of the Net Proceeds of the Issue of Shares, which took place in July 2002 when the Company floated on The GEM by Offering 1,307,000,000, 10-cent Shares at a Premium of \$HK1.90 per Share.

The Net Proceeds of this successful flotation was about \$HK2.38 billion, which has been slowly whittled down, ever since.

Today ... [CLICK TO ORDER FULL ARTICLE](#)

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

If readers feel that they would like to voice their opinions about that which they have read in TARGET, please feel free to e-mail your views to editor@targetnewspapers.com or targnews@hkstar.com. TARGET does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.